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On October 3, 2014, this report was posted as an MMWR Early 
Release on the MMWR website (http://www.cdc.gov/mmwr).
In August 2012, the California Department of Public Health 
(CDPH) was contacted by a San Francisco Bay area clinician 
who requested poliovirus testing for an unvaccinated man 
aged 29 years with acute flaccid paralysis (AFP) associated 
with anterior myelitis (i.e., evidence of inflammation of the 
spinal cord involving the grey matter including anterior horn 
cell bodies) and no history of international travel during the 
month before symptom onset. Within 2 weeks, CDPH had 
received reports of two additional cases of AFP with anterior 
myelitis of unknown etiology. Testing at CDPH’s Viral and 
Rickettsial Disease Laboratory for stool, nasopharyngeal swab, 
and cerebrospinal fluid (CSF) did not detect the presence of an 
enterovirus (EV), the genus of the family Picornaviridae that 
includes poliovirus. Additional laboratory testing for infectious 
diseases conducted at the CDPH Viral and Rickettsial Disease 
Laboratory did not identify a causative agent to explain the 
observed clinical syndrome reported among the patients. To 
identify other cases of AFP with anterior myelitis and elucidate 
possible common etiologies, CDPH posted alerts in official 
communications for California local health departments dur-
ing December 2012, July 2013, and February 2014. Reports of 
cases of neurologic illness received by CDPH were investigated 
throughout this period, and clinicians were encouraged to 
submit clinical samples for testing. A total of 23 cases of AFP 
with anterior myelitis of unknown etiology were identified. 
Epidemiologic and laboratory investigation did not identify 
poliovirus infection as a possible cause for the observed cases. 
No common etiology was identified to explain the reported 
cases, although EV-D68 was identified in upper respiratory 
tract specimens of two patients. EV infection, including 
poliovirus infection, should be considered in the differential 
diagnosis in cases of AFP with anterior myelitis and testing 
performed per CDC guidelines (1).
A case was defined as AFP in at least one limb consistent with 
anterior myelitis, as indicated by neuroimaging of the spine or 
electrodiagnostic studies (e.g., nerve conduction studies and 
electromyography), and with no known alternative etiology, 
in a person with symptom onset during January 2012–June 
2014. Among the 23 cases identified, younger persons and 
males were more frequently affected, with a median age of 
10 years (range = 1–73 years); 15 were aged <15 years, and 
56% were male. Similar to the race/ethnicity distribution in 
California, seven (30%) patients were white, six (26%) were 
Asian, six (26%) were Hispanic, one (4%) was black, one (4%) 
was of multiple race, and two (9%) were of unknown race. 
Affected patients resided in diverse geographic areas through-
out California with no indication of clustering. During the 
30-month inquiry, no indication of seasonality or temporal 
trends in disease onset was established (Figure).
Common features among the clinical presentations of 
patients included an upper respiratory or gastrointestinal 
prodrome <10 days before AFP onset (83%), CSF pleocytosis 
(83%), and absence of sensory deficits (78%). Ten patients 
(43%) also had concomitant mental status changes; eight 
patients (34%) had cranial nerve abnormalities. Patients 
typically had extended hospital stays (median = 17 days), and 
of 13 patients with available information, all had prolonged 
paralysis persisting at 60 days follow-up. Five patients were 
ventilator-dependent when discharged from the hospital to 
rehabilitation facilities, and one death was reported in an adult. 
Of 10 patients with mental status changes, eight (80%) had 
returned to baseline cognitive function at the time of discharge.
Specimens were available for testing from 19 (83%) of the 
patients. The CDPH Viral and Rickettsial Disease Laboratory 
tested nasopharyngeal or throat swabs (18), stool or rectal 
swabs (14), serum (17), and CSF (17) for evidence of recent 
infection with numerous infectious agents, including EVs 
(including poliovirus), arboviruses, herpes viruses (HSV-1, 
HSV-2, VZV, and EBV), parechoviruses, adenoviruses, rabies, 
influenza A and B, human metapneumovirus, respiratory 
syncytial virus, parainfluenza 1–4, Mycoplasma pneumoniae, 
rickettsial pathogens, and free-living amoebas. Results were 
unremarkable except for the following: 1) mycoplasma immu-
noglobulin M–positive serologies in two patients (these same 
patients had negative mycoplasma throat polymerase chain 
reaction [PCR] tests), 2) rhinovirus-positive PCR from a respi-
ratory specimen in one patient, and 3) EV-positive PCR from 
throat or upper respiratory tract specimens in two patients; 
these EVs were sequenced as EV-D68. Testing was limited 
by incomplete and late collection of specimens; respiratory 
samples collected <7 days of paralysis onset were submitted 
for nine (39%) patients, and stool or rectal specimens were 
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submitted for 15 (65%) patients. Specimens meeting World 
Health Organization (WHO) or CDC guidelines for polio-
virus detection (e.g., two stool specimens collected ≥24 hours 
apart and <14 days after symptom onset) were submitted for 
only two of the patients. Serologic testing was of limited value 
because specimens often were collected after patients had 
received intravenous immunoglobulin (IVIG) therapy.
Poliovirus was determined to be an unlikely etiology for any 
of the cases based on epidemiologic and limited laboratory 
investigation findings. Nonetheless, because AFP with anterior 
myelitis is the classic presentation of paralytic poliomyelitis, 
CDPH attempted to rule out poliovirus infection. Of 14 
patients with available information, 12 had previously received 
polio vaccine; one child and one adult were unvaccinated 
because of personal belief exemptions. Pre-IVIG serum was 
available from the unvaccinated child and tested negative for 
neutralizing antibodies against poliovirus at CDC laboratories. 
None of the patients reported travel out of the United States 
during the month before symptom onset.
Discussion
AFP has numerous etiologies and can prove diagnostically 
challenging; however, after the widespread implementation of 
polio vaccination worldwide, the subset of patients suffering 
from AFP with anterior myelitis is markedly smaller than the 
population of patients suffering from other forms of AFP. AFP 
is not a reportable syndrome in California, or any other U.S. 
state, other than as an occurrence of an unusual disease, and 
whether these cases represent an actual increase from baseline 
incidence of AFP with anterior myelitis in this population is 
unclear. A study examining AFP in children aged <15 years in 
California during 1992–1998 reported an incidence of 1.4 AFP 
cases per 100,000 children per year, with the most common 
diagnoses being Guillain-Barré syndrome (23%), unspecified 
AFP (21%), and botulism (12%). None of the 245 reviewed 
cases had recognized anterior myelitis, which is characteristic 
of paralytic poliomyelitis (2).
The etiology of AFP with anterior myelitis in the cases 
described in this report remains undetermined. EVs circulate 
widely in the United States, causing an estimated 10–15 mil-
lion symptomatic, mostly nonneurologic illnesses annually 
(2,3). EVs, other than poliovirus, are rarely known to result 
in AFP with anterior myelitis. EV-D68 infections in most 
patients manifest as purely respiratory illnesses. A single case of 
an EV-D68 infection associated with AFP has been reported in 
the literature (4), and an additional case was reported through 
nationwide EV surveillance (5). CDC is working with state and 
local health departments to better characterize the respiratory 
disease health burden and spectrum of illness associated with 
the recent increase in EV-D68 respiratory illness across the 
United States (6). The significance of EV-D68 detection in 
two of the cases in this report is unclear, particularly because it 
was detected in upper respiratory tract specimens and not CSF. 
However, EVs can prove challenging to identify as a cause of 
neurologic syndromes, including AFP. Poliovirus and EV-A71, 
well-documented causes of serious neurologic disease including 
FIGURE. Number of cases of acute flaccid paralysis with anterior myelitis (N = 23), by month of neurologic symptom onset — California, 
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poliomyelitis-like paralysis, are infrequently recovered from 
spinal fluid (7,8). In addition, delayed collection of laboratory 
specimens after respiratory illness and paralysis onset might 
have reduced the capacity to recover etiologic agents. 
Paralysis caused by poliovirus infection results from anterior 
horn cell injury and is characterized by poor recovery of motor 
function. Sensory loss, as reported in 22% of the cases in this 
report, is not a feature commonly associated with patients with 
paralysis because of poliovirus infection. However, sensory 
symptoms (e.g., pain and paresthesia) have been reported with 
poliovirus infections. The last cases of paralytic poliomyelitis 
caused by endemic transmission of wild poliovirus in the 
United States occurred in 1979. Global poliovirus eradication 
efforts have greatly reduced the risk for introduction of polio-
virus into the United States; wild-type poliovirus is currently 
endemic only in Afghanistan, Nigeria, and Pakistan; however, 
polio has been exported to countries that have previously 
been polio-free, and seven other countries have had cases or 
transmission of wild poliovirus in the last 12 months (9). 
Cases of vaccine-associated paralytic poliomyelitis cases do 
occur in countries using oral poliovirus vaccine (OPV) (10). 
OPV is no longer available in the United States; inactivated 
poliovirus vaccine has been recommended exclusively in the 
United States since 2000.
Although polio is no longer endemic in the United States, 
ruling out poliovirus infection in clinically compatible, unex-
plained cases of AFP, particularly those with anterior myelitis, 
is important to ensure that any importation of poliovirus is 
quickly identified and investigated. WHO and CDC have 
guidelines for epidemiologic, clinical, and laboratory investi-
gations of AFP to rule out poliovirus infection (10). Clinical 
and epidemiologic investigation should include a careful 
neurologic examination to characterize specific sensory (e.g., 
sensory symptoms versus sensory loss) as well as motor findings, 
querying patients about recent international travel (<30 days 
before onset), and contact with persons who recently traveled, 
particularly to regions with polio cases or regions where OPV 
is used. Documented history of vaccination and whether inac-
tivated poliovirus vaccine or OPV was administered should be 
noted, including dates of administration, number of doses, and 
manufacturer, if the information is available.
Specimens should be collected early during the course of 
disease for laboratory testing. Collection of specimens should 
follow CDC and WHO guidelines and include two stool speci-
mens collected ≥24 hours apart and <14 days after symptom 
onset, serum before administration of IVIG, and throat swabs. 
Of patients who had samples tested at the CDPH Viral and 
Rickettsial Disease Laboratory as described in this report, only 
two met the specifications for ruling out poliovirus infection 
as recommended by WHO or CDC guidelines*†§; all others 
lacked two stool specimens collected ≥24 hours apart and 
<14 days after symptom onset.
Paralytic poliomyelitis cases are immediately reportable to 
all state and local health departments in the United States. A 
confirmed paralytic poliomyelitis case should be reported to 
CDC within 4 hours after meeting notification criteria.
Although AFP with anterior myelitis or grey matter involve-
ment comprises a subset of patients with AFP, these cases can 
be challenging to distinguish at initial presentation before 
clinical, imaging, and laboratory study results are available. 
Thus, specimen collection to definitively rule out poliovirus 
infection from possible differential diagnoses should be con-
sidered among all patients with AFP of unknown etiology or 
a suspected viral etiology. This is particularly important for 
persons who are unimmunized and have a history of travel to 
countries with endemic polio or countries that use OPV for 
routine immunization.
Physicians treating patients with AFP of unknown etiology 
should work with their local and state health departments to 
* Additional information about CDC guidelines is available at http://www.cdc.
gov/vaccines/pubs/surv-manual/chpt12-polio.html. 
† Additional information about WHO guidelines are available at https://www.
hpsc.ie/hpsc/a-z/vaccinepreventable/polio/guidance/file,2461,en.pdf. 
§ Additional information about CDPH specimen collection guidelines for 
infectious disease testing in cases of neurologic illness is available at http://www.
cdph.ca.gov/programs/vrdl/pages/neurologicsurveillancetesting.aspx. 
What is already known on the topic?
Acute flaccid paralysis (AFP) with anterior myelitis is not a 
reportable condition, and baseline rates of disease are unknown 
but are likely quite low. Data from 1992–1998 on children aged 
<15 years in California indicated an incidence of 1.4 AFP cases per 
100,000 children per year and did not identify a single case of AFP 
with anterior myelitis. Viral causes of AFP with anterior myelitis 
include enteroviruses (including poliovirus), adenovirus, and 
flaviviruses such as West Nile virus. Enterovirus D68 has previ-
ously been reported to be associated with neurologic illness, 
although the scope of neurologic manifestations is unclear.
What is added by the report?
A total of 23 cases of AFP with anterior myelitis were identified 
during 2012–2014 in California. No common etiology was 
identified, although clinical laboratory findings supported a 
viral etiology. Two patients tested positive for enterovirus D68 
from upper respiratory specimens.
What are the implications for public health practice?
Poliovirus infection should be ruled out in all cases of AFP with 
anterior myelitis of unknown etiology. The scope of illness 
associated with enterovirus D68 might include neurologic 
manifestations, including AFP.
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rule out poliomyelitis early during the course of disease. To 
ensure adequate specimens for poliovirus testing, specimens 
should be collected according to CDC and WHO guidelines.
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